Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer Guidelines Pocket Guide - Guideline Central

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer

American Society of Clinical OncologyPublished: April 13, 2022

A PDF version of this Pocket Guide is also available!
$9.95
  • Key Points
  • Treatment
    • New Recommendation from 2022 Guideline Rapid Recommendation Update
    • Candidates
    • Measuring Response
    • Recommended Regimens for Patients with TNBC
    • Recommended Neoadjuvant Treatment for Patients with HER2-negative/HR-positive Breast Cancer
    • Recommended Neoadjuvant Treatment for Patients with HER2-Positive Disease


You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.